HANSOH PHARMA (03692.HK): Small Cell Lung Cancer Product HS-20093 Included in NMPA Priority Review Procedure
NewTimeSpace News: On 11 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692.HK) announced that, based on positive results from the pivotal Phase III trial ARTEMIS-008, Ruikang Lifutuota Monoclonal Antibody for injection (HS-20093) has been included in the priority review and approval procedure of China's National Medical Products Administration (NMPA) for the indication of small cell lung cancer that has failed platinum-containing treatment on 21 August 2026.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA
- HK Stock Connect Daily Report: ZJ INNOLIGHT Officially Added to Stock Connect, Z.AI Surges Over 12%, Southbound Net Buying Reaches HKD 3.18 Billion - 20260827
- HANSOH PHARMA(03692.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.26 billion, YoY increase of 35.82%
- HANSOH PHARMA (03692.HK): Self-Developed Class 1 New Drug HS-10582 Tablet Receives NMPA Clinical Trial Approval Notice for Primary Hypercholesterolemia
- Hansoh Pharmaceutical (03692.HK): HS-20093 Meets Primary Endpoint in Phase III Osteosarcoma Trial, to Advance NDA Filing
